Effects of oral administration of androstenedione on plasma androgens in young women using hormonal contraception

Effects of oral administration of androstenedione on plasma androgens in young women using hormonal contraception / Thomas Bassindale, David A. Cowan, Sian Dale, Andrew J. Hutt, Anthony R. Leeds, Michael J. Wheeler, Andrew T. Kicman. - (Journal of Clinical Endocrinology & Metabolism 89 (2004) 12 (1 December); p. 6030-6038)

  • PMID: 15579755
  • DOI: 10.1210/jc.2004-0790


Abstract

Androstenedione as a dietary supplement has been targeted at the sporting community, but there are limited data regarding its effects on plasma androgens in young women. A double-blind, cross-over study was undertaken involving 10 women (20-32 yr) using hormonal contraception. Because contamination of supplements has been reported, an in-house oral formulation was prepared containing purified androstenedione, the control being lactose only. After oral administration of a single dose of androstenedione (100 mg), blood was collected frequently up to 8 h and at 24 h. Maximum plasma androgen concentrations observed between volunteers were well above the upper limit of reference ranges for women, being 121-346 nmol/liter for androstenedione, 14-54 nmol/liter for testosterone (T), 11-32 nmol/liter for 5alpha-dihydrotestosterone, and 23-90 nmol/liter for 3alpha-androstanediol glucuronide. The free androgen index and T concentration changed in a similar manner. The mean change in area under the plasma concentration-time curve (0-24 h), compared with control data were: androstenedione approximately 7-fold, T approximately 16-fold, 5alpha-dihydrotestosterone approximately 9-fold, and 3alpha-androstanediol glucuronide approximately 5-fold; the mean conversion ratio of androstenedione to T was 12.5% (range 7.8-21.6%). Increases in T area under the plasma concentration-time curve were correlated with SHBG concentration (r = 0.80; P = 0.005). Formulation characteristics and SHBG levels appear to be important factors when considering plasma androgen increases after acute androstenedione administration.

Original document

Parameters

Science
Research / Study
Date
1 December 2004
People
Bassindale, Thomas
Cowan, David A.
Dale, Sian
Hutt, Andrew J.
Kicman, Andrew T.
Leeds, Anthony R.
Wheeler, Michael J.
Country
United Kingdom
Language
English
Other organisations
King's College London (KCL)
Laboratories
London, United Kingdom: Drug Control Centre
Doping classes
S1. Anabolic Agents
Substances
Androstenedione (androst-4-ene-3,17-dione)
Medical terms
Health effects
Various
Supplements
Document category
Scientific article
Document type
Pdf file
Date generated
2 December 2020
Date of last modification
5 December 2020
Category
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period
Origin